Chester County News and Community Website
BERWYN, PA — Panavance Therapeutics Inc. announced that an abstract regarding the Company’s tumor cell-selective and broadly active small molecule with a unique mechanism of action, GP-2250 (misetionamide), has been …
Panavance Therapeutics to Present Breakthrough Oncology Therapy at AACR 2023 Read More BERWYN, PA — Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023, at …
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event Read More BERWYN, PA — Panavance Therapeutics Inc. announced the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug Designation to GP-2250 for the treatment of all forms of pancreatic cancer.
Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 Read More
BERWYN, PA — Panavance Therapeutics Inc. announced the recent publication of positive data from a preclinical study evaluating GP-2250 for the treatment of pancreatic neuroendocrine carcinoma. The manuscript titled, “New …
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 Read More
BERWYN, PA — Panavance Therapeutics Inc. is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic …
Panavance Therapeutics Inc. Created to Transform Cancer Treatment Read More